EVALUATION OF THE PHARMACOKINETICS OF IVOSIDENIB, AN ORAL, TARGETED INHIBITOR OF MUTANT IDH1, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS.

Fan B.; Cohen M.; Nabhan S.; Liu H.; Liu G.; Bowden C.; Yang H.; Dai D.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >EVALUATION OF THE PHARMACOKINETICS OF IVOSIDENIB, AN ORAL, TARGETED INHIBITOR OF MUTANT IDH1, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS.

【24h】

EVALUATION OF THE PHARMACOKINETICS OF IVOSIDENIB, AN ORAL, TARGETED INHIBITOR OF MUTANT IDH1, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS.

机译：在健康日本和高加索科目中评价伊思凡替素，突变体IDH1的口腔靶向抑制剂的药代动力学。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2019年第1期|共1页
作者
Fan B.; Cohen M.; Nabhan S.; Liu H.; Liu G.; Bowden C.; Yang H.; Dai D.;
展开▼
作者单位

Agios Pharmaceut Inc Cambridge MA USA;

MBC Pharma Solut Newtown PA USA;

Agios Pharmaceut Inc Cambridge MA USA;

Agios Pharmaceut Inc Cambridge MA USA;

Agios Pharmaceut Inc Cambridge MA USA;

Agios Pharmaceut Inc Cambridge MA USA;

Agios Pharmaceut Inc Cambridge MA USA;

Agios Pharmaceut Inc Cambridge MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. EVALUATION OF THE PHARMACOKINETICS OF IVOSIDENIB, AN ORAL, TARGETED INHIBITOR OF MUTANT IDH1, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS. [J] . Fan B., Cohen M., Nabhan S., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：在健康日本和高加索科目中评价伊思凡替素，突变体IDH1的口腔靶向抑制剂的药代动力学。
2. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. [J] . Vaidyanathan S, Jermany J, Yeh C, British Journal of Clinical Pharmacology . 2006,第6期

机译：Aliskiren是一种新型口服有效的肾素抑制剂，在日本和高加索受试者中显示出相似的药代动力学和药效学。
3. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects [J] . KadokuraT., KashiwaM., GroenendaalD., Biopharmaceutics and Drug Disposition . 2013,第8期

机译：口服直接因子Xa抑制剂darexaban在健康的白种人和日本受试者中的临床药代动力学，药效学，安全性和耐受性
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. C-Reactive Protein as a Biomarker of Oral Health and Risk of Cardiovascular Disease in Healthy and CV Disease Subjects. [D] . Alzalzalah, Ahmed. 2017

机译：C反应蛋白是健康和CV疾病受试者口腔健康和心血管疾病风险的生物标志物。
6. Discovery of AG-120 (Ivosidenib): A First-in-ClassMutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers [O] . Janeta Popovici-Muller, ∇, René M. Lemieux, 2018

机译：发现AG-120（伊沃西尼布）：一流突变IDH1抑制剂用于治疗IDH1突变癌症
7. The Comparative Pharmacokinetics and Safety of the Oral Neuraminidase Inhibitor Oseltamivir when Given in Multiple Doses to Healthy Japanese and Caucasian Subjects. [O] . G. He, J. Massarella, J.L. Ruckle, 2000

机译：口腔神经氨酸酶抑制剂Oseltamivir的比较药代动力学和安全性，当多剂量给健康日本和白种人对象时。

EVALUATION OF THE PHARMACOKINETICS OF IVOSIDENIB, AN ORAL, TARGETED INHIBITOR OF MUTANT IDH1, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS.

著录项

相似文献

相关主题

期刊订阅